Three-year mortality and amputation data for Lutonix 014 Drug-Coated Balloon
Below-The-Knee IDE trial presented at LINC
(Leipzig, Germany) January 29, 2020 – BD (Becton, Dickinson and Company) today announced that interim findings from the Lutonix below-the-knee (BTK) IDE trial show positive safety results at three years for freedom from mortality, freedom from major amputation and amputation-free survival.
The clinical study is a prospective, global, multicenter, single blind, randomized (2:1 randomization), controlled trial comparing the Lutonix 014 drug coated balloon (DCB) to percutaneous transluminal angioplasty (PTA) for the treatment of narrowed or obstructed arteries below the knee. The safety endpoints were assessed using a Kaplan-Meier (K-M) analysis through 36 months for the intent-to-treat population, with 70% of patients having completed three-year follow up at the time of analysis. At 1095 days, there is no significant difference in freedom from mortality (DCB: 81.0% and PTA: 81.0%, P=.946), freedom from major amputation (DCB: 95.5% and PTA: 93.8%, P=.268) or amputation-free survival (DCB: 77.8% and PTA: 77.8%, P=.495). Lutonix 014 DCB demonstrated statistically improved primary efficacy at six months when compared to PTA (K-M analysis), with K-M curves merging at one year. There were no statistical differences in safety or efficacy beyond six months in this interim analysis. These results were presented at the Leipzig Interventional Course (LINC) 2020 Annual Conference in Leipzig, Germany, and show that versus PTA, the Lutonix 014 DCB provided statistically significant efficacy outcomes at six months with no observed safety issues out to three years
The Lutonix 014 DCB has been commercially available n Europe, Canada and Australia for treatment of the below-the-knee arteries in patients with CLI since 2013. The product is an investigational device in the U.S.